Physician profile
John G Stratidis
NPI 1922036987
$541.39
in general payments reported to CMS, 2019-2025
9 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.64 · 2020: $23.46 · 2021: $27.09 · 2022: $29.90 · 2023: $64.23 · 2024: $144 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.91 | 2023-2025 | Dalvance |
| Insmed, INC. | $119.25 | 2022-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $69.23 | 2020-2025 | Nuzyra |
| Viiv Healthcare Company | $48.25 | 2021-2025 | Cabenuva |
| Smith+Nephew, INC. | $45.56 | 2019-2024 | Collagenase Santyl |
| Cumberland Pharmaceuticals, INC. | $32.94 | 2022-2024 | Vibativ |
| Kerecis Limited | $32.60 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Merck Sharp & Dohme LLC | $17.21 | 2025 | Zerbaxa |
| Organogenesis INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stratidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.